Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 22, 2017
What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?
TEVA PHARM has two hundred and sixty-seven approved drugs.| Patents: | 31 |
| Tradenames: | 223 |
| Ingredients: | 216 |
| NDAs: | 267 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
omacetaxine mepesuccinate | for Injection | 3.5 mg/vial | SYNRIBO | 10/26/2016 |
omeprazole | Delayed-release Tablets | 20 mg | OMEPRAZOLE | 6/3/2015 |
glatiramer acetate | Injection | 40 mg/mL, 1 mL pre-filled syringe | COPAXONE | 2/26/2014 |
glatiramer acetate | Injection | 40 mg/mL, 1 mL pre-filled syringe | COPAXONE | 1/29/2014 |
cyclobenzaprine hydrochloride | Extended-release Capsule | 15 mg and 30 mg | AMRIX | 8/11/2008 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,108,010 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 7,842,687 | Cephalotaxane derivatives and their processes of preparation and purification | ► Subscribe | |||||||||||||||||||||||||||
| 9,526,851 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 6,655,381 | Pre-metered dose magazine for breath-actuated dry powder inhaler | ► Subscribe | |||||||||||||||||||||||||||
| 8,877,245 | Modified release dosage forms of skeletal muscle relaxants | ► Subscribe | |||||||||||||||||||||||||||
| 7,169,774 | Cephalotaxane derivatives and their processes of preparation and purification | ► Subscribe | |||||||||||||||||||||||||||
| 9,174,013 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 9,737,674 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 9,526,850 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| 9,533,111 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portugal | 2405749 | ► Subscribe | |||||||||||||||||||||||||||
| Austria | 506094 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 1294420 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 101628934 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 7011301 | ► Subscribe | |||||||||||||||||||||||||||
| Germany | 69923768 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 2514463 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 2177223 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 20160038057 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2779347 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB98/030 | United Kingdom | ► Subscribe | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 | ||||||||||||||||||||||||||
| C0103 | Belgium | ► Subscribe | PRODUCT NAME: CALCII ATORVASTATINUM TRIHYDRICUM (=ATORVASTATINUM); NAT. REGISTRATION NO/DATE: 19 IS 95 F 3 19970922; FIRST REGISTRATION: GB PL/00018/0240 19961107 | ||||||||||||||||||||||||||
| C/GB06/008 | United Kingdom | ► Subscribe | PRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919 | ||||||||||||||||||||||||||
| C0030 | France | ► Subscribe | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 | ||||||||||||||||||||||||||
| /1998 | Austria | ► Subscribe | PRODUCT NAME: RIZATRIPTAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE RIZATRIPTANBENZOAT; NAT. REGISTRATION NO/DATE: 1-22636 - 1-22639 19980709; FIRST REGISTRATION: NL 21815 - 21818 19980211 | ||||||||||||||||||||||||||
| /2013 | Austria | ► Subscribe | PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317 | ||||||||||||||||||||||||||
| C/GB98/043 | United Kingdom | ► Subscribe | PRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512 | ||||||||||||||||||||||||||
| C/GB98/027 | United Kingdom | ► Subscribe | PRODUCT NAME: TOLTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: SE 13475 19970905; SE 13476 19970905; UK 00032/0222 19980203; UK 00032/0223 19980203 | ||||||||||||||||||||||||||
| 2016000120 | Germany | ► Subscribe | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713 | ||||||||||||||||||||||||||
| 2015000093 | Germany | ► Subscribe | PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,741 others who get our Drug Patent Expiration Alerts:
